-
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (EVOMELA®).
-
Bringing life-changing therapeutics to China and the world.
September 10, 2019
CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at https://www.youtube.com/channel/UC5IBDAqhTqt5esL9r3dgQRQ.
August 12, 2019
EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.
Press Release
November 09, 2020
Press Release
November 05, 2020
CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.
EVOMELA® (melphalan) for Injection, ZEVALIN® (ibritumomab tiuxetan), and MARQIBO® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.
© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.
